In August, OCRA hosted a listening session with the U.S. Food and Drug Administration (FDA) to better understand the impact of Covid-19 on clinical trial participation.
Watch the full FDA listening session in the video below.
Related Topics
The Overview: May 2025
Global Collaborative Research Push Resonates Across Airwaves The launch of the Global Ovarian Cancer Research Consortium has garnered significant media attention, with coverage appearing on NBC News Radio, FOX 5 Washington D.C., KUNS-TV … Continued
OCRA’s Advocate’s Corner: May 2025
FY26 Budget Watch, Advocacy Results, and State-Level Progress As Congress ramps up work on the FY26 federal budget, advocates are focused on maintaining vital cancer programs and advancing state policies … Continued
OCRA Sponsors NCCN 2025 Guidelines for Cervical Cancer Patients
This article was updated in May 2025 to reflect NCCN’s release of the 2025 Guidelines for Cervical Cancer Patients. OCRA is a proud sponsor of 2025 Cervical Cancer Updates. We … Continued